Omentin-1 vs Epoetin Alfa
Head-to-head comparison of Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) and Epoetin Alfa (Recombinant human erythropoietin alfa) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Omentin-1 | Epoetin Alfa |
|---|---|---|
| Category | Diabetes & Metabolic | Muscle & Performance |
| Full Name | Omentin-1 (Intelectin-1, ITLN1) | Recombinant human erythropoietin alfa |
| Molecular Weight | ~35 kDa | ≈30,400 Da |
| Half-Life | hours | ~4-13 h IV; ~20-30 h SC |
| Amino Acids | 313 | 165 |
| Typical Dose | No approved human dose; research use only | 50-100 IU/kg SC 3x weekly or 40,000 IU SC weekly |
| Route | IV|SC | Subcutaneous/IV |
| Purity | ≥98% | ≥98% |
| Studies Count | 82 | 320 |
| Research Status | Pre-clinical | Clinical |
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
Epoetin Alfa Benefits
- ✓raises hemoglobin
- ✓increases oxygen-carrying capacity
- ✓may increase VO2 max
- ✓improves time-to-exhaustion
Omentin-1 Dosing
not established|not established
Epoetin Alfa Dosing
50-100 IU/kg subcutaneous 3x weekly|40,000 IU subcutaneous weekly|Titrate to hemoglobin target under medical supervision
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Epoetin Alfa Side Effects
- ⚠hypertension
- ⚠thrombosis
- ⚠polycythemia
Research Overview
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
Epoetin Alfa
Human studies in anemia and performance-related settings show that increasing red-cell mass can improve aerobic capacity and endurance. It remains heavily regulated because excessive erythropoiesis raises thrombotic and cardiovascular risk.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.